PDF(Pubmed)
Abstract：
UNASSIGNED: Haemostatic spray (HS; Hemospray) is a powder agent for endoscopic haemostasis in patients with acute upper gastrointestinal bleeding (UGIB). It has been shown to be effective and easy to administer. However, published data on efficacy and safety in children remain scarce. Our aim was to describe our experience with the use of HS in the management of UGIB.
UNASSIGNED: A retrospective review was conducted of patients aged 0-18 receiving HS for endoscopic haemostasis from January 2017 to December 2021. Information was obtained on demographics, clinical presentation and comorbidities. Outcomes were successful initial haemostasis and rates of re-bleeding.
UNASSIGNED: A total of 25 applications of HS occurred in 23 patients. The median patient age was 8 years (range: 4 months to 16 years). HS was used in 17/25 (68%) applications as monotherapy. Other treatments employed were clip application and adrenaline injection. One hundred per cent initial haemostasis was achieved with three (13.0%) patients who experienced re-bleeding. All patients tolerated HS applications with no adverse events.
UNASSIGNED: Our finding supports the use of HS in the management of UGIB in children. HS, either as monotherapy or in combination with other conventional therapy, could potentially be the treatment of choice in children with UGIB with its excellent feasibility and good safety profile.
UNASSIGNED: A retrospective review was conducted of patients aged 0-18 receiving HS for endoscopic haemostasis from January 2017 to December 2021. Information was obtained on demographics, clinical presentation and comorbidities. Outcomes were successful initial haemostasis and rates of re-bleeding.
UNASSIGNED: A total of 25 applications of HS occurred in 23 patients. The median patient age was 8 years (range: 4 months to 16 years). HS was used in 17/25 (68%) applications as monotherapy. Other treatments employed were clip application and adrenaline injection. One hundred per cent initial haemostasis was achieved with three (13.0%) patients who experienced re-bleeding. All patients tolerated HS applications with no adverse events.
UNASSIGNED: Our finding supports the use of HS in the management of UGIB in children. HS, either as monotherapy or in combination with other conventional therapy, could potentially be the treatment of choice in children with UGIB with its excellent feasibility and good safety profile.
摘要：
■止血喷雾剂（HS；Hemospray）是一种用于急性上消化道出血（UGIB）患者内镜止血的粉末剂。它已被证明是有效和易于管理。然而,关于儿童疗效和安全性的公布数据仍然很少。我们的目的是描述我们在UGIB管理中使用HS的经验。
■从2017年1月至2021年12月，对0-18岁接受HS内镜止血的患者进行了回顾性审查。获得了人口统计信息，临床表现和合并症。结果是成功的初始止血和再出血率。
■23例患者共应用了25例HS。患者年龄中位数为8岁（范围：4个月至16岁）。HS在17/25（68％）的应用中用作单一疗法。采用的其他治疗是夹子应用和肾上腺素注射。三名（13.0％）患者出现再出血，达到了100％的初始止血。所有患者均耐受HS应用，无不良事件。
■我们的发现支持在儿童UGIB管理中使用HS。HS,作为单一疗法或与其他常规疗法联合使用，有可能成为UGIB患儿的首选治疗方法，其可行性和安全性良好。
■从2017年1月至2021年12月，对0-18岁接受HS内镜止血的患者进行了回顾性审查。获得了人口统计信息，临床表现和合并症。结果是成功的初始止血和再出血率。
■23例患者共应用了25例HS。患者年龄中位数为8岁（范围：4个月至16岁）。HS在17/25（68％）的应用中用作单一疗法。采用的其他治疗是夹子应用和肾上腺素注射。三名（13.0％）患者出现再出血，达到了100％的初始止血。所有患者均耐受HS应用，无不良事件。
■我们的发现支持在儿童UGIB管理中使用HS。HS,作为单一疗法或与其他常规疗法联合使用，有可能成为UGIB患儿的首选治疗方法，其可行性和安全性良好。
